All reports

Belgian guidelines for economic evaluations and budget impact analyses: third edition

KCE Reports 400C (2025) In Belgium, cost-effectiveness is one of the criteria used by public authorities to assess applications for reimbursement of medicines and Class 1 medical devices, i.e. products for which the applicant claims added therapeutic value and for which a higher price may be charged.

Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation

KCE Reports 368C (2023)

An EQ-5D-5L value set for Belgium – How to value health-related quality of life?

KCE Reports 342C (2021) For a long time, decisions on whether to reimburse a health intervention have taken into account the impact of the illness and its treatment on patient life expectancy and quality of life. For life expectancy, there is a clear measure: time.

Anticoagulants in non-valvular atrial fibrillation

KCE Reports 279C (2016) Anticoagulants are prescribed, among others, to people with a heart rhythm disorder called atrial fibrillation, in order to reduce their risk of stroke. In recent years, “new oral anticoagulants” or NOAC’s have arrived on the market.

Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

KCE Reports 276C (2016)

Use of pneumococcal vaccines in the elderly: an economic evaluation

KCE Reports 274C (2016)

Left ventricular assist devices in the treatment of end-stage heart failure

KCE Reports 264C (2016)

Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology

KCE Reports 240C (2015)

A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

KCE Reports 231C (2014)

Seasonal influenza vaccination: prioritizing children or other target groups? - Part II

KCE Reports 204C (2013)

Transcatheter Aortic Valve Implantation (TAVI): a Health Technology Assessment Update

KCE Reports 163C (2011)

[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

KCE Reports 157 (2011)

Home Oxygen Therapy

KCE Reports 156C (2011) People suffering from chronic lung diseases need sometimes an oxygen complement at the house. In Belgium, this treatment can be prescribed without restriction by any doctor and one notes a clear increase in the expenditure these last years. Several authorities of decisions are implied in the organization of oxygen treatment, just like of the professional bodies or deprived, and there is a lack of integrated approach.

Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood

KCE Reports 155C (2011)

[Cost-utility of Vaccination against Chickenpox in Children and against Herpes Zoster in Elderly in Belgium]

KCE Reports 151 (2010)

Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

KCE Reports 127C (2010)

All reports

21 results

Belgian guidelines for economic evaluations and budget impact analyses: third edition

Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation

An EQ-5D-5L value set for Belgium – How to value health-related quality of life?

Anticoagulants in non-valvular atrial fibrillation

Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

Use of pneumococcal vaccines in the elderly: an economic evaluation

Left ventricular assist devices in the treatment of end-stage heart failure

Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology

A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

Seasonal influenza vaccination: prioritizing children or other target groups? - Part II

Transcatheter Aortic Valve Implantation (TAVI): a Health Technology Assessment Update

[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

Home Oxygen Therapy

Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood

[Cost-utility of Vaccination against Chickenpox in Children and against Herpes Zoster in Elderly in Belgium]

Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: Health Technology Assessment

Threshold values for cost-effectiveness in health care

Effects and costs of pneumococcal conjugate vaccination of Belgian children

[Leukoreduction. A possible measure in the context of a national blood safety policy]

You are here

All reports

General domain

Publication year

Results

21 results

Belgian guidelines for economic evaluations and budget impact analyses: third edition

Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation

An EQ-5D-5L value set for Belgium – How to value health-related quality of life?

Anticoagulants in non-valvular atrial fibrillation

Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

Use of pneumococcal vaccines in the elderly: an economic evaluation

Left ventricular assist devices in the treatment of end-stage heart failure

Next generation sequencing gene panels for targeted therapy in oncology and haemato-oncology

A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

Seasonal influenza vaccination: prioritizing children or other target groups? - Part II

Transcatheter Aortic Valve Implantation (TAVI): a Health Technology Assessment Update

[Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

Home Oxygen Therapy

Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood

[Cost-utility of Vaccination against Chickenpox in Children and against Herpes Zoster in Elderly in Belgium]

Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: Health Technology Assessment

Threshold values for cost-effectiveness in health care

Effects and costs of pneumococcal conjugate vaccination of Belgian children

[Leukoreduction. A possible measure in the context of a national blood safety policy]

Pages